News
photo source:
Posted by: Daniela Socolovschi
News / Social
25 Jan. 2021 / 17:48
The list of reimbursed medicines has been expanded
The list of reimbursed drugs from the compulsory health insurance funds was completed with six common international names indicated in the treatment of ten diseases, informs the National Medical Insurance Company (CNAM).
Thus, three drugs will be fully compensated. These include deflazacort for the treatment of autoimmune diseases, including rheumatoid arthritis, rare diseases such as bullous epidermolysis, muscular dystrophy. The other two are: levetiracetam for the treatment of epilepsy, as well as an innovative drug, aripiprazole, prescribed to children up to 18 years of age in both schizophrenia and moderate to severe manic episodes.
Patients will receive a 70% price compensation for cabergolinum, prescribed for hyperprolactinemia - a condition characterized by high blood levels of a hormone called prolactin). At the same time, deflazacort will be indicated in the treatment of asthma, being compensated in proportion of 70% for adults and 100% for children up to 18 years.
Two other preparations will have a compensation rate of 30%. These include memantinum, a drug used to treat Alzheimer's disease, and rosuvastatin for the treatment of cardiovascular diseases associated with dyslipidemia.
Some of the preparations included in this list also refer to the treatment of some diseases for which there were no compensated drugs until now. These diseases are: dyslepidemia, hyperprolactinemia, Duchenne muscular dystrophy and moderate to severe manic episodes.
According to the NHIC, in 2021, over 678 million lei were planned in the compulsory health insurance funds for compensated pharmaceutical preparations.
Currently, the list of reimbursed medicines includes 158 international common names and can be found at the family doctor, in pharmacies, at CNAM Info (0 800 99999) and accessed on the CNAM website, under the heading “Reimbursed Medicines”.
Patients will receive a 70% price compensation for cabergolinum, prescribed for hyperprolactinemia - a condition characterized by high blood levels of a hormone called prolactin). At the same time, deflazacort will be indicated in the treatment of asthma, being compensated in proportion of 70% for adults and 100% for children up to 18 years.
Two other preparations will have a compensation rate of 30%. These include memantinum, a drug used to treat Alzheimer's disease, and rosuvastatin for the treatment of cardiovascular diseases associated with dyslipidemia.
Some of the preparations included in this list also refer to the treatment of some diseases for which there were no compensated drugs until now. These diseases are: dyslepidemia, hyperprolactinemia, Duchenne muscular dystrophy and moderate to severe manic episodes.
According to the NHIC, in 2021, over 678 million lei were planned in the compulsory health insurance funds for compensated pharmaceutical preparations.
Currently, the list of reimbursed medicines includes 158 international common names and can be found at the family doctor, in pharmacies, at CNAM Info (0 800 99999) and accessed on the CNAM website, under the heading “Reimbursed Medicines”.
Latest News
News / Economic
27 Nov. 2022 / 21:16
Over 70 domestic entrepreneurs exhibited their products at the "Cămara Fest" fair
News / Social
27 Nov. 2022 / 18:18
The Anticorruption Prosecutor's Office appealed to the Supreme Court of Justice on the case of Igor Dodon
News / Regional
27 Nov. 2022 / 16:43
Exhibition-fair of exotic birds at Soroca Citadel
News / Political
27 Nov. 2022 / 14:00
PAS National Council meets to discuss the strategy for the local elections
News / Social
27 Nov. 2022 / 13:41
Environment Agency recommends the use of alternative means of transport to reduce the level of air pollution
News / Political
27 Nov. 2022 / 12:49
Bogdan Aurescu and Antony Blinken will discuss Romania's support to the Republic of Moldova
News / International
27 Nov. 2022 / 12:04
Snow to blanket Kyiv from Sunday as power still in short supply
News / Social
27 Nov. 2022 / 11:18
Show Comments